

## **Wockhardt's Q2 Results 2008**

# **Sales grow by 48.3% to Rs. 935 crore Operating Profit up by 51.6%**

**Mumbai, July 28, 2008**

Pharmaceutical and biotechnology major Wockhardt Limited today announced a 48.3% increase in consolidated sales revenues to stand at Rs. 935 crore for the second quarter ended June 30, 2008 over the corresponding quarter of 2007. Operating profit grew by 51.6% to Rs. 230.8 crore. Net profit stood at Rs. 95.9 crore.

### **USA Business:**

The overall US business grew by 128% in Q2 of 2008. Wockhardt USA Inc. and Morton Grove Pharmaceuticals having gained critical mass are showing phenomenal growth and are performing as per target plans. Currently, the US business contributes 19% to Wockhardt's revenues. There were 5 ANDA approvals during this period with a total of 61 products being marketed in the US market.

### **Europe Business:**

Wockhardt's European business grew by 30% in Q2 of 2008 and continues to be Wockhardt's single largest market accounting for 50% of consolidated sales. In Europe, Wockhardt UK is a key growth driver growing by 10% against the generic market growth of 6%.

### **India Business:**

As per ORG-IMS for Q2-2008, Wockhardt's India business grew by over 20%; thereby improving its ranking to the 15<sup>th</sup> position. The biotech portfolio too is growing steadily with sales of Wosulin showing tremendous promise. Overall 9 brands feature in the list of 'Top 300' brands of the industry with Dexolac and Spasmo-Proxyvon still maintaining its position in the 'Top 100'.

Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme. Wockhardt has global footprints including UK, France, Germany, Ireland and USA. Wockhardt employs a multi-cultural and multi-ethnic workforce of 6500 people worldwide belonging to 14 different nationalities.

**WOCKHARDT LIMITED**  
**UNAUDITED CONSOLIDATED FINANCIAL RESULTS**  
**FOR THE QUARTER ENDED 30TH JUNE, 2008**



(RS IN MILLION)

PARTICULARS	Quarter Ended 30/06/2008	% To Sales	Quarter Ended 30/06/2007	% To Sales	Growth%	Six Months Ended 30/06/2008	% To Sales	Six Months Ended 30/06/2007	% To Sales	Growth%	Year Ended 31/12/2007
Income from operations	9,350	100.0	6,303	100.0	48.3	17,207	100.0	11,531	100.0	49.2	26,532
Total Expenditure	7,042	75.3	4,781	75.9	47.3	13,162	76.5	8,850	76.7	48.7	20,141
a) (Increase)/Decrease in stock	(443)	(4.7)	(527)	(8.4)	(15.9)	-1,210	(7.0)	(672)	(5.8)	80.1	-1,431
b) Consumption of raw material	1,974	21.1	1,508	23.9	30.9	3,803	22.1	3,053	26.5	24.6	7,374
c) Purchase of Finished Goods	1,673	17.9	1,325	21.0	26.3	3,178	18.5	1,975	17.1	60.9	3,985
Material Consumption	3,204	34.3	2,306	36.6	38.9	5,771	33.5	4,356	37.8	32.5	9,928
d) Staff Cost	1,614	17.3	1,063	16.9	51.8	3,159	18.4	1,874	16.3	68.6	4,433
e) R & D Expenditure	218	2.3	140	2.2	55.7	361	2.1	300	2.6	20.3	505
f) Other expenditure	2,006	21.5	1,272	20.2	57.7	3,871	22.5	2,320	20.1	66.9	5,275
Other Expenditure	3,838	41.0	2,475	39.3	55.1	7,391	43.0	4,494	39.0	64.5	10,213
Gross Profit before Interest, Depreciation & Taxation	2,308	24.7	1,522	24.1	51.6	4,045	23.5	2,681	23.3	50.9	6,391
Financing Cost (Net) [Refer Note 2]	880	9.4	85	1.3	935.3	1,445	8.4	214	1.9	575.2	974
Gross Profit after Interest but before Depreciation & Taxation	1,428	15.3	1,437	22.8	-0.6	2,600	15.1	2,467	21.4	5.4	5,417
Depreciation	252	2.7	172	2.7	46.5	493	2.9	353	3.1	39.7	785
Profit after Interest & depreciation	1,176	12.6	1,265	20.1	(7.0)	2,107	12.2	2,114	18.3	(0.3)	4,632
Other Income	22	-	25	-	-	67	-	47	-	-	110
Profit before Tax	1,198	12.8	1,290	20.5	(7.1)	2,174	12.6	2,161	18.7	0.6	4,742
Provision for Taxation	163	1.7	177	2.8	(7.9)	294	1.7	301	2.6	(2.3)	527
Fringe Benefit Tax	8	0.1	9	0.1	(11.1)	18	0.1	18	0.2	0.0	36
Deferred Taxation	90	1.0	80	1.3	12.5	154	0.9	155	1.3	(0.6)	354
Profit After Tax	937	10.0	1,024	16.2	(8.5)	1,708	9.9	1,687	14.6	1.2	3,825
Add: Share of Profit/ (Loss) from Associates	22	0.2	0			39	0.2	0			33
Net Profit	959	10.3	1,024	16.2	(6.3)	1,747	10.2	1,687	14.6	3.6	3,858
Extra Ordinary Income/ (Expense) (Net of Tax) [Refer Note 3]	104	1.1	0			(175)	(1.0)	0			0
Net Profit After Extra-Ordinary Item	1,063	11.4	1,024	16.2	3.8	1,572	9.1	1,687	14.6	(6.8)	3,858
Paid-up Equity Share Capital (Rs.5/-each)	547		547		-	547		547		-	547
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-		-	-		-		-	12,188
Basic & Diluted Earning Per Share before Extra- Ordinary Item (Rs)	8.77		9.35		(6.2)	15.96		15.42		3.5	35.25
Basic & Diluted Earning Per Share after Extra-Ordinary Item (Rs)	9.72		9.35		4.0	14.37		15.41		(6.7)	35.25
Public Shareholding											
- Number of Shares	2,80,75,803		2,80,52,203			2,80,75,803		2,80,52,203			2,80,75,803
- Percentage to Paid-up Capital	25.66%		25.63%			25.66%		25.63%			25.66%





